New Jersey, US: In the latest update on the vaccination front, Johnson & Johnson said on Thursday that its single-shot COVID-19 vaccine has shown promising signs of protection against the delta variant that is rapidly spreading across the US and other countries.
The findings were confirmed after a small laboratory study, the company reports, where the vaccine demonstrated strong, persistent activity against the new Delta and other highly prevalent SARS-CoV-2 viral variants.
Read also | India records 46K coronavirus cases in last 24 hours, Covid death toll below 1000
Two preprint study summaries have been submitted to BioRxiv, a non-profit preprint server for the life sciences.
What are the major findings?
Research has shown that the permanence of the immune response lasted at least eight months, the length of time that has been evaluated to date. Mathai Maimon, MD, PhD, global head of Johnson & Johnson’s Janssen Research and Development, said: “The current eight months of data studied so far suggest that the single-shot Johnson & Johnson COVID-19 vaccine is a strong neutralizing antibody. produces a response that does not subside; rather, we see improvement over time. In addition, we observe a sustained and notably strong, durable cellular immune response.”
According to the report, Johnson & Johnson’s single-dose vaccine elicited an even higher level of neutralizing antibody action against the delta version than was recently observed for the beta (b.1.351) version in South Africa.
The US-manufacturer’s vaccine demonstrated 85 percent efficacy against severe/critical disease in its ensemble trial and demonstrated protection against hospitalization and death. The vaccine demonstrated effectiveness in all regions studied globally, including South Africa and Brazil. These countries showed a high prevalence of rapidly emerging beta and zeta variants during the study period.
Paul Stoffels, Vice President and Chief Scientific Officer of the Executive Committee at Johnson & Johnson, said: “Today’s newly announced studies reinforce the potential of the Johnson & Johnson COVID-19 vaccine to help protect the health of people globally. “
“We believe that our vaccine provides durable protection against COVID-19 and has neutralizing activity against the delta variant. This adds to the robust body of clinical data that concerns our single-shot vaccine. Supports the ability to protect against multiple types,” Stoffels said.
Where is the vaccine available now?
The vaccine has been made available on a non-profit basis in many regions and countries during periods of emergency pandemics. The vaccine was approved for emergency use authorization (EUA) in the United States on 27 February and conditional marketing authorization (CMA) by the European Commission on 11 March.
(with inputs from ANI)
See below health equipment-
Calculate your body mass index (BMI)
.